Naloxone does not appear to have psychotomimetic properties, whereas the other powerful narcotic antagonists I have mentioned, cyclazocine, cyclorphan, and nalorphine, have. Pentazocine, which is a weak narcotic antagonist, apparently has this psychotomimetic capacity only to a minor degree, although one group of investigators has observed a reasonably high incidence of bizarre subjective effects in patients receiving the drug by mouth in doses which have appeared benign when given parenterally by other investigators.
It is fascinating that at least two of these antagonists, nalorphine and cyclazocine, appear to be capable of producing physical dependence. The abstinence syndromes on withdrawal of these drugs are clear-cut, although not morphine-like. The post-addicts who have served as experimental subjects in these experiments seem to have little or no desire for the effects produced by these drugs, so that their liability for abuse by potential addicts seems slight.
These compounds, whatever their ultimate role in medicine, have illustrated the possibility of dissociating certain effects which have often been assumed in the past to be linked inseparably in analgesics possessing the power of morphine. The patterns of respiratory effect, psychotomimesis, and abstinence phenomena seen after these antagonists indicate important differences between the antagonists and related nonantagonist analgesic drugs. 
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Abstract
The complex mechanisms that maintain the blood pressure can be interfered with at many points by drugs. A drug acting at one point may be potentiated by another which blocks a compensatory reflex minimizing the effect of the first. Many therapeutically useful drug combinations have a nonspecific mechanism of this kind although drugs that act upon different points in the sympathetic efferent vasomotor pathway have not been proved to have a useful additive effect. It is not easy to prove a synergistic action of two drugs unless it is large. The best supported examples are combinations of either a diuretic or a vasodilator with a sympathetic blocking drug. These combinations are the ones most widely used in treatment of hypertension. They allow the dose of each active substance to be reduced so that unwanted side-effects are decreased without losing the desired action on the blood pressure.
Drug combinations have special risks besides their obvious advantages. Patients are more likely to become confused and take the wrong doses if their treatment regime is complicated. Two drugs which are individually nontoxic may have dangers when used together. Oliguria and a mounting blood urea may follow combined use of powerful modern diuretics. Toxic effects may be entirely unrelated to the main therapeutic action of the drug, as with the enhanced diabetogenic effect of diazoxide used with hydrochlorothiazide.
Several potent cardiovascular drugs modify the response to drugs which might be given to raise the blood pressure in an emergency. No drug in common therapeutic use seriously reduces the response to injected noradrenaline but some, such as sympathetic blockers and monoamine oxidase inhibitors, greatly increase sensitivity. Pressor amines that act indirectly by noradrenaline release may be ineffective in the presence of drugs which deplete or insulate the stores of the transmitter in adrenergic nerve endings.
The advantages and disadvantages of drug interactions deserve more thought and study than they usually receive.
Polypharmacy is a word used in a derogatory sense to describe the simultaneous use of a number of drugs without a rational pharmacological basis. In many ways this is a fair description of present practice in the treatment of hypertension, for it is by no means unusual for three or four different drugs to be administered in combination. The reason for this policy is the difficulty of controlling blood pressure and the relatively high incidence of side-effects exhibited by most drugs used to treat hypertension. The first effective drugs to be the treatment of hypertension hydrallazine and the quaternar ganglion-blocking drugsall had a of unpleasant side-effects. These that treatment had to be restrict with malignant and other severe fi tension and many found the sympi by the drugs almost as bad as the Since the frequency and severity were related to the dose, empir suggested that combinations of might preserve some of the ar action while minimizing the side one drug. Some combinations wer have become a part of generally ac practice. Clinical trials, properlI compare the efficiency of drug have taken a long time to complet( recently that some of the longest l tions have been subjected to critical sympathetic nervous system using information use fed back from baroreceptors in many parts of the heart and peripheral circulation. Other mech-Mechanism anisms such as the output of noradrenaline by the Depletes nor-adrenals and the regulation of sodium and water adrenaline balance by the kidneys also play a part. principal sites of action is given in Table 1 . Many act at more than one point.
The action of a drug combination can be introduced for understood by considering the adaptations that reserpine, take place after administration of a diuretic or ry ammonium vasodilator alone. A diuretic, such as chlorohigh incidence thiazide, causes an acute reduction of blood were so severe volume but circulatory changes are compensated Led to patients by arteriolar and veno-constriction so that there orms of hyperis only a small fall in blood pressure and cardiac toms produced output (Winer 1961) . A vasodilator, such as e disease itself. hydrallazine, dilates peripheral arterioles but the of side-effects resultant fall in blood pressure is minimized by â ical reasoning reflex rise in heart rate and output (Moyer & smaller doses Brest 1961) . ntihypertensive Sympathetic blocking drugs inhibit these -effects of any homeostatic mechanisms and so increase the fall e effective and in blood pressure. Furthermore, some sympaxcepted clinical thetic inhibitors are more effective at high rates y designed to of traffic (Paton & Zaimis 1952 , Boura & Green combinations, 1963 , so that proportionately more impulses are e and it is only blocked if concurrent administration of a drug used combinasuch as hydrallazine or a diuretic has increased review.
sympathetic activity.
The Rationale of Combined Drug Treatment
Drugs may interact either because of a specific pharmacological effect on a receptor or enzyme or because of some general alteration in the body physiology which increases sensitivity to the drug. Specific pharmacological interactions among antihypertensive drugs are less common than nonspecific reactions. Page (1961) postulates a 'mosaic' of physiological factors which control the blood pressure and in which interference with one may have an important influence on others. Maintenance of the blood pressure involves a continuous adjustment of the balance between peripheral resistance and cardiac output. The main regulatory activity is mediated by the Evaluation of Dr-ug Combinationis Precise evaluation of drug interactions in man is not easy. Two methods are used, acute titration and long-term fixed-dose studies. In animal pharmacology it is possible to monitor the blood pressure continuously and observe thle effects of intravenous test doses alone and in combination. This method can be applied in man and has the advantage that most of the physiological alterations that take place can be measured. Use of this method to demonstrate potentiation of a ganglion-blocking drug by reserpine is shown in Fig 1, using data taken from Harington (1956) .
It is more difficult to use this technique if there is a long delay in onset of the effect (as with in blood pressure in a group of6 men who were given the same test dose of hexamethonium before and several houirs after a parenteral dose of 3 mg reserpine reserpine and methyldopa) or if the acute effect is different from the long-term one. For example, parenteral guanethidine causes a short-lived pressor response before the blood pressure falls.
The alternative is to study the effects of prolonged administration in a double-blind or crossover clinical trial, although this can be laborious. In a recent study (Smith et al. 1964 ) over 1,000 patients were screened to find 300 who were suitable for a comparison of the effects of rauwolfia, hydrallazine and chlorothiazide ( Table  2) . The most effective regime proved to be chlorothiazide-rauwolfia, a combination evolved from clinical observations some years before.
One problem of a trial of this type is to ensure that each drug is given in an effective dose. The Administration of an adjuvant such as chlorothiazide moves the whole curve to the left (dotted line). If both druigs have a steep dose-response an additive effect may be missed ifeither is given at too low a dose (a) on that particular individual's response curve. Ideally, both should be given in the effective range (b) but this may be difficult to predict (Fig 2) . Some adjuvants such as chlorothiazide shift the whole dose-response curve to the left and the effect of a fixed dose of this diuretic is easily detected. If both agents have a steep dose-response curve and individual sensitivity varies considerably, as it does with guanethidine and methyldopa, selection of a satisfactory dose presents almost insuperable difficulties. Although it has been suggested that methyldopa and guanethidine may have a useful additive effect this could not be demonstrated in acute studies (Dollery & Harington 1961) .
Clinical Use ofCombined Drug Treatment
Combined drug treatment is used for hypertension of all grades of severity. Patients with moderate hypertension often respond to a mixture of reserpine and a thiazide diuretic (Table 2) . Those with more severe hypertension are usually treated with methyldopa or guanethidine but a high proportion are given a diuretic to potentiate th-effect. This often reduces the dose needed (Fig 3) and minimizes side-effects.
A complex regime of treatment creates problems for both doctor and patient. It may be difficult to know what effect any particular constituent is having and this applies to both beneficial and toxic actions of drugs. New drugs should always be evaluated alone before they are used with other agents; otherwise trials may be misleading.
Patients who have to take several different drugs at a variety of doses and times are more likely to make errors or omissions in their treatment. One tablet may be confused with another in a patient's mind. An error of this kind led one of my patients to take 6 g a day of chlorothiazide for a month, fortunately without ill effect. Combined tablets are useful, although often expensive, when a fixed dose is used. It is unwise to prescribe combined tablets when the dose range of one constituent is wide, e.g. guanethidine, bethanidine.
Combined drug treatment is often condemned on the ground of cost but it can be more economical than giving a single drug. In the Hypertension Clinic at Hammersmith Hospital 134 patients are being treated with methyldopa and 91 of them are Blood pressure controlled at first with 120 mg guanethidine, later reduced to 70 mg daily with a diuretic. After several years the dose of guanethidine was reduced further to 50 mg daily, probably because the patient's pressure control had been reset at a lower level also taking hydrochlorothiazide. Assuming that 50% more methyldopa would be needed to control these patients if the diuretic were removed, the difference in cost can be calculated. An outlay of £16 per week on hydrochlorothiazide saves an estimated sum of £53 per week on methyldopa: a net-saving of £37 per week or about 8s weekly for each patient.
Interactions with Pressor Drugs
Patients with cardiovascular disease may suffer hypotension following blood loss, myocardial infarction or an overdose of antihypertensive drugs. Their reactions to pressor substances may be altered by drugs given to treat hypertension or angina. Most sympathetic blocking drugs and monoamine oxidase inhibitors potentiate the pressor action of noradrenaline (Fig 4) . Drugs that deplete catecholamines from nerve endings (reserpine, guanethidine, methyldopa) decrease or abolish the pressor response to amines such as methylamphetamine whose main action is mediated by release of noradrenaline from stores. Bretylium and bethanidine cause less severe depletion of catecholamines but may inhibit their release and also diminish the response to indirect pressor amines (Boura & Green 1963) . Sensitivity to tyramine, methylamphetamine and other noradrenaline releasing agents may be dangerously increased after treatment with monoamine oxidase inhibitors. If a pressor drug is necessary, noradrenaline is the drug of choice since none of the drugs in common therapeutic use antagonizes its action. The dose used should be small, beginning with about one-tenth of that normally employed, for not only is the sensitivity of the patient increased but the duration of action is prolonged (Fig 4) . If necessary intravenous phentolamine will block the effects of exogenous noradrenaline. A trial drug, P.385, which was a powerful antihypertensive, also had an adrenolytic effect. A patient became hypotensive on this drug and was almost completely unresponsive to noradrenaline. This patient's blood pressure rose spontaneously but angiotensin would be the logical pressor substance to use in a similar situation if hypotension was dangerous or prolonged.
A guide to patients' responses to noradrenaline and a typical indirectly acting amine, methylamphetamine, is given in Table 3 . Some of this information is taken from animal pharmacology (Dollery et al. 1963 , Boura & Green 1963 , McCubbin et al. 1961 , Moyer & Brest 1961 , Winer 1961 .
Toxic Interactions
Some drug combinations are valuable, many are useless and a few are dangerous. Powerful combinations of antihypertensive drugs may cause severe hypotension but the risks of syncope can be minimized by frequent measurements of blood pressure while dose adjustments are being made.
Complications such as increased toxicity of digitalis preparations after potassium depletion caused by diuretics should be anticipated and are easily countered. Insidious or unexpected toxic actions are a greater hazard. Patients are surprisingly sensible in their suspicion of drug combinations. They often enquire if it is safe to take one drug when they are already on another. Although a patient may, incorrectly, visualize a toxic drug interaction as a fizzing chemical reaction in his stomach rather than a selective damage to cells or enzymes, it would be wise if doctors paid more attention to the safety of drug combinations. One potent hypotensive drug, pargyline, belongs to the class of monoamine oxidase inhibitors with its special risks.
The increased potency of new drugs often causes new toxic reactions. Diazoxide was an antihypertensive produced as a result of a successful attempt to separate the antihypertensive and diuretic properties of chlorothiazide. As it caused fluid retention, use in combination with a standard benzothiadiazine diuretic was advised. The two drugs together proved to be extremely potent diabetogenic agents (Dollery et al. 1962 ) and having been withdrawn from trial in hypertension they proved of value in treating hypoglycxmia produced by insulin-secreting tumours (Ernesti etal. 1965 ).
More powerful diuretics have made it possible to produce a greater degree of sodium depletion and are of value in managing severe heart failure and in improving control of blood pressure in patients with the most severe forms of hypertension. However, the combination of powerful diuretics may remove so much salt and water from the body that the blood urea rises rapidly ( Fig 5) . Every time a physician adds to the number of drugs a patient is taking he may devise a novel combination that has a special risk. Frequent use of new drug combinations requires separate investigation with animal toxicity studies and clinical observation carried out as thoroughly as the primary trial of a single new drug.
Conclusion
Combinations of antihypertensive drugs are widely used in the treatment of cardiovascular disease, especially hypertension, because they minimize the toxic effects of each individual drug and have an additive therapeutic effect. In many instances the advantages and risks of these drug combinations have not been studied adequately. In future, pharmacological and therapeutic aspects of combined treatment must be approached with the same care and thought that is now applied in the best studies of new drugs.
